DMT210 Topical Gel in the Treatment of Acne Rosacea

• Status: Completed
• Trial end date: 2017-08-30
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the safety, tolerability, and efficacy of DMT210 Gel, 5% when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Half of participants will receive DMT210 Gel while the other half will receive vehicle control.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dermata Therapeutics

Criteria

Inclusion Criteria:

• Patient is male or non-pregnant female at least 18 years of age.

• Clinical diagnosis of moderate to severe facial rosacea as determined by Investigator's Global Assessment (IGA) at Randomization

• Patient has at least ten inflammatory lesions of rosacea on the face at Randomization

• Patient is willing to apply the Investigational Product as directed

• Patient is willing and able to comply with the protocol

Exclusion Criteria:

• Patient is pregnant or planning to become pregnant

• Patient is taking a topical therapy which may affect the patient's rosacea